March quarterly activity and cashflow report
Filed with ASX · · 11 pages · English
Earlier from Argent Biopharma
- MGC pharma to acquire medical research company MediCaNL
- Investor presentation
- Mxc completes first ArtemiC order, March qtr record revenue
- Ethics Committee Approval Granted Phase III Clinical Trial
- SwissPharmaCan AG increases initial purchase order
Later from Argent Biopharma
- ArtemiC submitted to Health Canada
- $1M order for ArtemiC Rescue from swiss PharmaCan
- Further findings on ArtemiC as anti-inflammatory agent
- CimetrA patent submitted to European IP office
- MGC pharma 2021 clinical trials program update
Follow Argent Biopharma into a list and get an email when it puts out news.
Follow Argent Biopharma